MARKET

CBIO

CBIO

Crescent Biopharma Inc
NASDAQ
17.33
+0.49
+2.91%
Closed 16:15 08/10 EDT
OPEN
16.84
PREV CLOSE
16.84
HIGH
17.69
LOW
16.72
VOLUME
256.33K
TURNOVER
0
52 WEEK HIGH
27.41
52 WEEK LOW
8.72
MARKET CAP
643.70M
P/E (TTM)
-2.3386
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CBIO last week (0803-0807)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO)
TipRanks · 08/04 02:10
Weekly Report: what happened at CBIO last week (0727-0731)?
Weekly Report · 08/03 09:39
Crescent Biopharma Announces Grants of Inducement Awards
Barchart · 08/03 06:30
Crescent Biopharma (CBIO) Gets a Buy from Wedbush
TipRanks · 07/31 15:48
Analysts Offer Insights on Healthcare Companies: Pasithea Therapeutics Corp (KTTA), Crescent Biopharma (CBIO) and Dexcom (DXCM)
TipRanks · 07/31 10:30
Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway
TipRanks · 07/30 20:35
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Benzinga · 07/30 12:14
More
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Webull offers Crescent Biopharma Inc stock information, including NASDAQ: CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.